New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2013
06:47 EDTPDLIPDL BioPharma announces departure of Principal Accounting Officer Krumel
Caroline Krumel resigned from her position as VP of Finance and Principal Accounting Officer effective immediately. Krumel did not advise the company of any disagreements over any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure. The company will begin a search for a new Finance VP.
News For PDLI From The Last 14 Days
Check below for free stories on PDLI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
18:02 EDTPDLIPDL BioPharma issues statement on resignation of corporate auditors
PDL BioPharma was orally notified by its independent registered accounting firm, Ernst & Young, or EY, that it was resigning effective September 11. The resignation was confirmed in a letter delivered to the company on September 15, and reported in PDL's Form 8-K filed on September 16. PDL has issued the following statement in response to the announcement: "We have received a number of inquiries on the reason for the resignation of EY. We were surprised by the resignation as we did not have any disagreements with EY on accounting practices, scope or procedures nor did we have any reportable events that would have caused EY to resign their position as our auditors," stated Peter Garcia, VP and CFO of PDL. "We thank EY for their years of service to the company and have already begun the process of appointing new auditors, which we expect to announce in the coming weeks. We currently expect to continue our financial reporting in a timely manner." PDL BioPharma dropped 12% today following the revelation of Ernst & Young's resignation as corporate auditors.
10:48 EDTPDLIHigh option volume stocks
Subscribe for More Information
September 9, 2014
18:31 EDTPDLIOn The Fly: After Hours Movers
Subscribe for More Information
16:04 EDTPDLIPDL BioPharma sees Q3 revenue $165M, consensus $149.25M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use